Patents by Inventor Joakim Glamann

Joakim Glamann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-KIR combination treatments and methods
    Patent number: 10253095
    Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 9, 2019
    Assignees: INNATE PHARMA S.A.S., NOVO NORDISK A/S
    Inventors: Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
  • Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies
    Patent number: 9333255
    Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 10, 2016
    Assignees: Innate Pharma S.A.S., Novo Norkisk A/S
    Inventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
  • Compositions and Methods for Treating Viral Infection
    Publication number: 20140023646
    Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
    Type: Application
    Filed: October 1, 2013
    Publication date: January 23, 2014
    Applicants: Innate Pharma S.A.S., Novo Norkisk A/S
    Inventors: Peter Andreas, Nicolai, Reumert WAGTMANN, Francois ROMAGNE, Joakim GLAMANN
  • Methods of treating viral infections by administering KIR2DL-binding antibodies
    Patent number: 8551483
    Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: October 8, 2013
    Assignees: Innate Pharma S.A.S., Novo Nordisk A/S
    Inventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
  • ANTI-KIR COMBINATION TREATMENTS AND METHODS
    Publication number: 20110293561
    Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
    Type: Application
    Filed: July 15, 2011
    Publication date: December 1, 2011
    Applicants: INNATE PHARMA S.A.S., NOVO NORDISK A/S
    Inventors: FRANCOIS ROMAGNÉ, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
  • Anti-Kir Combination Treatments and Methods
    Publication number: 20090196850
    Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
    Type: Application
    Filed: January 6, 2006
    Publication date: August 6, 2009
    Applicants: NOVO NORDISK A/S, INNATE PHARMA S.A.S.
    Inventors: Francois Romagne, Peter Andreas Nicolai Reu Wagtmann, Joakim Glamann
  • Compositions and Methods for Treating Viral Infection
    Publication number: 20090035305
    Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
    Type: Application
    Filed: January 6, 2006
    Publication date: February 5, 2009
    Applicants: Novo Nordisk A/S, Innate Pharma S.A.S.
    Inventors: Peter Andreas Wagtmann, Francois Romagne, Joakim Glamann